newsfilter
← Latest News
Business Wire·

Auna Announces 2Q26 Financial Results

  • Auna reported second quarter 2026 consolidated revenue of S/1,238 million, representing a 9% FX-neutral increase & a 13% year-over-year reported increase.
  • Adjusted EBITDA decreased 9% FX-neutral & 6% year-over-year on a reported basis to S/227 million, with an Adjusted EBITDA margin of 18.4%.
  • Operating cash flow rose 45% year-over-year, while free cash flow surged 181% year-over-year due to disciplined working capital management & improved collections.
  • The leverage ratio improved to 3.6x, moving closer to the medium-term target of below 3.0x.
  • Operational volume metrics increased year-over-year: surgeries by 5.2% to 21,912, hospital days by 5% to 135,107, & chemotherapy & radiotherapy sessions by 15%.
  • Revenue growth varied by market: 4% in Mexico, 8% in Peru, & 13% in Colombia, driven by new B2B memberships, high-complexity procedure volumes, & risk-sharing contract expansions.
  • Adjusted EBITDA declines were attributed to service mix changes, temporary margin pressure in Mexico & Colombia, higher pharmacy & payroll costs, & accepted penalties related to prior-year billing reconciliations in Peru.
  • Auna reaffirmed full-year 2026 revenue guidance near the midpoint of its 10% to 14% FX-neutral range, approximately 12%, while noting temporary cost pressures for Adjusted EBITDA.
  • Net income for the quarter was S/33 million, down from S/84 million in the prior year period, primarily due to a reduction in non-cash foreign exchange gains on net finance costs.
  • Adjusted net income was S/40 million, compared to S/89 million in the prior year period, also impacted by foreign exchange fluctuations on finance costs.
  • Capital expenditure guidance remains unchanged at approximately 4% of revenues.